Loading...
Market
Number of new clinical trials involving Imfinzi
2
Resolution / Starting Odds
0-5 new trials • 33%
6-10 new trials • 33%
More than 10 new trials • 33%
ClinicalTrials.gov database
Story
FDA Approves Imfinzi Combo for dMMR Advanced Endometrial Cancer
Jun 17, 2024, 08:12 AM
The U.S. Food and Drug Administration (FDA) has approved the use of durvalumab in combination with carboplatin and paclitaxel, followed by single-agent durvalumab, for adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR). This approval, announced on June 14, is based on the Duo-E subgroup analysis. Durvalumab, marketed as IMFINZI®, is produced by AstraZeneca (AZN).
View original story
Similar markets
0-5 trials • 25%
6-10 trials • 25%
11-15 trials • 25%
More than 15 trials • 25%
0 • 25%
1 - 2 • 25%
3 - 4 • 25%
5 or more • 25%
0-2 trials • 25%
3-5 trials • 25%
6-8 trials • 25%
More than 8 trials • 25%
0-5 trials • 25%
6-10 trials • 25%
11-15 trials • 25%
More than 15 trials • 25%
0-5 • 25%
6-10 • 25%
11-15 • 25%
More than 15 • 25%
0-5 trials • 25%
6-10 trials • 25%
11-15 trials • 25%
More than 15 trials • 25%
Lung cancer • 25%
Breast cancer • 25%
Colorectal cancer • 25%
Other • 25%
Less than $1 billion • 25%
$1 billion - $2 billion • 25%
$2 billion - $3 billion • 25%
More than $3 billion • 25%
0-1 • 25%
2-3 • 25%
4-5 • 25%
More than 5 • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
